Impact of COVID-19 on inpatient referral of acute heart failure: a single-centre experience from the south-west of the UK.


Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
04 2021
Historique:
revised: 10 11 2020
received: 05 08 2020
accepted: 22 11 2020
pubmed: 8 1 2021
medline: 10 4 2021
entrez: 7 1 2021
Statut: ppublish

Résumé

Healthcare services worldwide have been significantly impacted by the COVID-19 pandemic. Recent reports have shown a decline in hospitalization for emergency cardiac conditions. The impact of the COVID-19 pandemic on hospitalization and particularly mortality due to acute heart failure has not been thoroughly described. In this single-centre observational study, we examined referrals to the acute heart failure team over a period of 16 weeks (7 January to 27 April 2020) spanning the ongoing COVID-19 pandemic; 283 patients referred to our acute heart failure services over the study period were included on the basis of typical symptoms, raised BNP, and echocardiogram. There was a substantial but statistically non-significant drop in referrals with 164 referred in the 8 weeks before the first UK death due to COVID-19 on 2 March 2020 (BC), compared with 119 referred after (AC) in the subsequent 8 weeks, representing a 27% reduction overall (P = 0.06). The 30 day case fatality rate was increased from 11% in the BC group compared with 21% in the AC group (risk ratio = 1.9, 95% confidence interval 1.09-3.3). Age, gender, length of stay, left ventricular ejection fraction, and N-terminal pro-brain natriuretic peptide were similar between the groups. Admission creatinine, age, and AC cohort status were found to be univariable predictors of mortality. On multivariate Cox regression analysis, only age (hazard ratio 1.04, P = 0.03) and AC cohort status (hazard ratio 2.1, P = 0.017) remained significant predictors of mortality. On sensitivity analysis, this increased mortality was driven by COVID-19 positive status. There was a reduction in referral of patients with acute heart failure with significant increase in mortality in the 8 weeks following the first reported UK death due to COVID-19. The observation of increased mortality does not appear related to a change in population in terms of demographics, left ventricular ejection fraction, or N-terminal pro-brain natriuretic peptide. The observed increased mortality appears to be related to the coexistence of COVID19 infection with acute heart failure. The study highlights the need for widespread preventative and shielding measures particularly in this group of patients especially in the light of the second wave. Longer follow-up with inclusion of data from other centres and community heart failure services will be needed.

Identifiants

pubmed: 33410281
doi: 10.1002/ehf2.13158
pmc: PMC8006615
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1691-1695

Informations de copyright

© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

Références

BMJ. 2019 Feb 13;364:l223
pubmed: 30760447
Eur J Heart Fail. 2020 Dec;22(12):2219-2224
pubmed: 32809274
Eur J Heart Fail. 2020 Dec;22(12):2205-2215
pubmed: 32833283
N Engl J Med. 2020 Aug 13;383(7):691-693
pubmed: 32427432
J Card Fail. 2020 Jun;26(6):462-463
pubmed: 32405232
JAMA. 2003 Nov 19;290(19):2581-7
pubmed: 14625335
Eur J Heart Fail. 2020 Jun;22(6):1045-1046
pubmed: 32469132
Am Heart J. 2017 Jan;183:40-48
pubmed: 27979040
Circ Heart Fail. 2020 Jun;13(6):e007274
pubmed: 32482087
ESC Heart Fail. 2021 Apr;8(2):1691-1695
pubmed: 33410281
Eur Heart J Qual Care Clin Outcomes. 2020 Jul 1;6(3):221-222
pubmed: 32502261
Eur Heart J. 2006 Jan;27(1):65-75
pubmed: 16219658
Eur J Heart Fail. 2020 Jun;22(6):978-984
pubmed: 32478951
J Am Coll Cardiol. 2020 Jun 9;75(22):2871-2872
pubmed: 32283124

Auteurs

Gemina Doolub (G)

North Bristol NHS Trust, Bristol, UK.

Chih Wong (C)

North Bristol NHS Trust, Bristol, UK.

Lynsey Hewitson (L)

North Bristol NHS Trust, Bristol, UK.

Ahmed Mohamed (A)

North Bristol NHS Trust, Bristol, UK.

Fraser Todd (F)

North Bristol NHS Trust, Bristol, UK.

Laisha Gogola (L)

North Bristol NHS Trust, Bristol, UK.

Andrew Skyrme-Jones (A)

North Bristol NHS Trust, Bristol, UK.
University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.

Shahid Aziz (S)

North Bristol NHS Trust, Bristol, UK.
University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.

Eva Sammut (E)

University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
University of Bristol, Bristol, UK.

Amardeep Dastidar (A)

North Bristol NHS Trust, Bristol, UK.
University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
University of Bristol, Bristol, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH